Summary
What if we could finally treat metastatic patients and uncurable cancers like sarcomas ?
HEPHAISTOS-Pharma developed ONCO-Boost, the first-in-class intravenous TLR4 immunostimulant that will be a game changer in immunotherapy. This innovation was discovered after 40 years of research from a woman entrepreneur who developed a mature, scalable, disruptive and eco-friendly platform. ONCO-Boost can cure hard to treat cancers as a stand-alone treatment but can also increase the efficacy of existing treatments. Our cure is injected intravenously and this changes everything, we can offer therapeutic options for patients with metastatic cancers and hardly accessible tumors. As such, ONCO-Boost can cure 10x more patients than competitors, all limited to intratumoral injection. HEPHAISTOS' ambition is to become the European leader in immunostimulants, with a platform able to supply the market with large quantities of drugs, able to save millions of patients each year.
HEPHAISTOS-Pharma developed ONCO-Boost, the first-in-class intravenous TLR4 immunostimulant that will be a game changer in immunotherapy. This innovation was discovered after 40 years of research from a woman entrepreneur who developed a mature, scalable, disruptive and eco-friendly platform. ONCO-Boost can cure hard to treat cancers as a stand-alone treatment but can also increase the efficacy of existing treatments. Our cure is injected intravenously and this changes everything, we can offer therapeutic options for patients with metastatic cancers and hardly accessible tumors. As such, ONCO-Boost can cure 10x more patients than competitors, all limited to intratumoral injection. HEPHAISTOS' ambition is to become the European leader in immunostimulants, with a platform able to supply the market with large quantities of drugs, able to save millions of patients each year.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101145244 |
| Start date: | 01-05-2024 |
| End date: | 28-02-2026 |
| Total budget - Public funding: | 6 910 955,50 Euro - 2 499 999,00 Euro |
Cordis data
Original description
What if we could finally treat metastatic patients and uncurable cancers like sarcomas ?HEPHAISTOS-Pharma developed ONCO-Boost, the first-in-class intravenous TLR4 immunostimulant that will be a game changer in immunotherapy. This innovation was discovered after 40 years of research from a woman entrepreneur who developed a mature, scalable, disruptive and eco-friendly platform. ONCO-Boost can cure hard to treat cancers as a stand-alone treatment but can also increase the efficacy of existing treatments. Our cure is injected intravenously and this changes everything, we can offer therapeutic options for patients with metastatic cancers and hardly accessible tumors. As such, ONCO-Boost can cure 10x more patients than competitors, all limited to intratumoral injection. HEPHAISTOS' ambition is to become the European leader in immunostimulants, with a platform able to supply the market with large quantities of drugs, able to save millions of patients each year.
Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)
